192 related articles for article (PubMed ID: 16316599)
1. Proteomics and diabetic nephropathy.
Merchant ML; Klein JB
Curr Diab Rep; 2005 Dec; 5(6):464-9. PubMed ID: 16316599
[TBL] [Abstract][Full Text] [Related]
2. Study of diabetic nephropathy in the proteomic era.
Thongboonkerd V
Contrib Nephrol; 2011; 170():172-183. PubMed ID: 21659770
[TBL] [Abstract][Full Text] [Related]
3. Proteomics and diabetic nephropathy.
Merchant ML; Klein JB
Semin Nephrol; 2007 Nov; 27(6):627-36. PubMed ID: 18061845
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
5. Urinary exosomes and diabetic nephropathy: a proteomic approach.
Raimondo F; Corbetta S; Morosi L; Chinello C; Gianazza E; Castoldi G; Di Gioia C; Bombardi C; Stella A; Battaglia C; Bianchi C; Magni F; Pitto M
Mol Biosyst; 2013 Jun; 9(6):1139-46. PubMed ID: 23344851
[TBL] [Abstract][Full Text] [Related]
6. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes.
Zubiri I; Posada-Ayala M; Benito-Martin A; Maroto AS; Martin-Lorenzo M; Cannata-Ortiz P; de la Cuesta F; Gonzalez-Calero L; Barderas MG; Fernandez-Fernandez B; Ortiz A; Vivanco F; Alvarez-Llamas G
Transl Res; 2015 Nov; 166(5):474-484.e4. PubMed ID: 26072307
[TBL] [Abstract][Full Text] [Related]
7. Proteomics in diabetic nephropathy.
Kim HJ; Yoo HS; Kim CW
Proteomics Clin Appl; 2008 Mar; 2(3):301-11. PubMed ID: 21136835
[TBL] [Abstract][Full Text] [Related]
8. New insights into the use of biomarkers of diabetic nephropathy.
Jha JC; Jandeleit-Dahm KA; Cooper ME
Adv Chronic Kidney Dis; 2014 May; 21(3):318-26. PubMed ID: 24780461
[TBL] [Abstract][Full Text] [Related]
9. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases.
Wang G; Ouyang J; Li S; Wang H; Lian B; Liu Z; Xie L
J Transl Med; 2019 Aug; 17(1):264. PubMed ID: 31409386
[TBL] [Abstract][Full Text] [Related]
10. Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?
Papale M; Di Paolo S; Vocino G; Rocchetti MT; Gesualdo L
J Nephrol; 2014 Jun; 27(3):221-8. PubMed ID: 24567069
[TBL] [Abstract][Full Text] [Related]
11. The pathogenesis of diabetic nephropathy: focus on microRNAs and proteomics.
Conserva F; Pontrelli P; Accetturo M; Gesualdo L
J Nephrol; 2013; 26(5):811-20. PubMed ID: 23543479
[TBL] [Abstract][Full Text] [Related]
12. Proteomic discovery of diabetic nephropathy biomarkers.
Merchant ML; Klein JB
Adv Chronic Kidney Dis; 2010 Nov; 17(6):480-6. PubMed ID: 21044770
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.
Qi W; Keenan HA; Li Q; Ishikado A; Kannt A; Sadowski T; Yorek MA; Wu IH; Lockhart S; Coppey LJ; Pfenninger A; Liew CW; Qiang G; Burkart AM; Hastings S; Pober D; Cahill C; Niewczas MA; Israelsen WJ; Tinsley L; Stillman IE; Amenta PS; Feener EP; Vander Heiden MG; Stanton RC; King GL
Nat Med; 2017 Jun; 23(6):753-762. PubMed ID: 28436957
[TBL] [Abstract][Full Text] [Related]
14. Terpenoids in Diabetic Nephropathy: Advances and Therapeutic Opportunities.
Kaushik M; Kaushik A; Chaudhary J; Jain A
Endocr Metab Immune Disord Drug Targets; 2024; 24(1):13-30. PubMed ID: 37680163
[TBL] [Abstract][Full Text] [Related]
15. Urinary afamin levels are associated with the progression of diabetic nephropathy.
Kaburagi Y; Takahashi E; Kajio H; Yamashita S; Yamamoto-Honda R; Shiga T; Okumura A; Goto A; Fukazawa Y; Seki N; Tobe K; Matsumoto M; Noda M; Unoki-Kubota H
Diabetes Res Clin Pract; 2019 Jan; 147():37-46. PubMed ID: 29522788
[TBL] [Abstract][Full Text] [Related]
16. Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes.
Zhang D; Yang H; Kong X; Wang K; Mao X; Yan X; Wang Y; Liu S; Zhang X; Li J; Chen L; Wu J; Wei M; Yang J; Guan Y
Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E287-95. PubMed ID: 20959534
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN).
Yuan Y; Sun H; Sun Z
Lipids Health Dis; 2017 Jun; 16(1):126. PubMed ID: 28659153
[TBL] [Abstract][Full Text] [Related]
18. Role of sirtuin-1 in diabetic nephropathy.
Wang W; Sun W; Cheng Y; Xu Z; Cai L
J Mol Med (Berl); 2019 Mar; 97(3):291-309. PubMed ID: 30707256
[TBL] [Abstract][Full Text] [Related]
19. Insights into predicting diabetic nephropathy using urinary biomarkers.
Khan NU; Lin J; Liu X; Li H; Lu W; Zhong Z; Zhang H; Waqas M; Shen L
Biochim Biophys Acta Proteins Proteom; 2020 Oct; 1868(10):140475. PubMed ID: 32574766
[TBL] [Abstract][Full Text] [Related]
20. Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy.
Jiang H; Guan G; Zhang R; Liu G; Cheng J; Hou X; Cui Y
Diabetes Metab Res Rev; 2009 Mar; 25(3):232-41. PubMed ID: 19177462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
